Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mymd Pharmaceuticals Inc (NQ: MYMD )

1.965 -0.045 (-2.24%)
Streaming Delayed Price Updated: 2:00 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mymd Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Five Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBD
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced on Thursday the results from a preclinical study of its investigational cannabinoid Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD)... 
Via Benzinga
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
From MyMD Pharmaceuticals, Inc.
Via Business Wire
More Personal Portfolio: Biotech, Commodities, And Gold
In a few years we will know if that was an extraordinarily opportunistic moment, or a long and frustrating rabbit hole. 
Via Talk Markets
MyMD Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by over 1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! 
Via InvestorPlace
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for a look at the biggest pre-market stock movers as we check out the latest news worth reading on Tuesday morning! 
Via InvestorPlace
Why Is MyMD Pharmaceuticals Stock Gaining Today?
MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announced topline results from its randomized Phase 2 study of oral TNF-α inhibitor, MYMD-1, in patients with chronic inflammation associated with 
Via Benzinga
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. 
Via Benzinga
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
MyMD Joins LOT Network To Protect Company And Shareholders From Patent Trolls
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) has joined LOT Network, the international, non-profit community of companies working together to protect themselves against litigation brought on by patent... 
Via Benzinga
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
DEA Concludes MyMD's Supera-CBD Is Not A Controlled Substance Or Listed Chemical
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced that the U.S. Drug Enforcement Administration has conducted a scientific review and determined that investigational cannabinoid Supera-CBD is not... 
Via Benzinga
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
From MyMD Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.